B Cells in Breast Cancer Pathology

Mengyuan Li; Angela Quintana; Elena Alberts; Miu Shing Hung; Victoire Boulat; Mercè Martí Ripoll; Anita Grigoriadis

doi:10.3390/cancers15051517

B Cells in Breast Cancer Pathology

Mengyuan Li, Angela Quintana, Elena Alberts, Miu Shing Hung, Victoire Boulat, Mercè Martí Ripoll, Anita Grigoriadis

Comprehensive Cancer Centre

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

B cells have recently become a focus in breast cancer pathology due to their influence on tumour regression, prognosis, and response to treatment, besides their contribution to antigen presentation, immunoglobulin production, and regulation of adaptive responses. As our understanding of diverse B cell subsets in eliciting both pro- and anti-inflammatory responses in breast cancer patients increases, it has become pertinent to address the molecular and clinical relevance of these immune cell populations within the tumour microenvironment (TME). At the primary tumour site, B cells are either found spatially dispersed or aggregated in so-called tertiary lymphoid structures (TLS). In axillary lymph nodes (LNs), B cell populations, amongst a plethora of activities, undergo germinal centre reactions to ensure humoral immunity. With the recent approval for the addition of immunotherapeutic drugs as a treatment option in the early and metastatic settings for triple-negative breast cancer (TNBC) patients, B cell populations or TLS may resemble valuable biomarkers for immunotherapy responses in certain breast cancer subgroups. New technologies such as spatially defined sequencing techniques, multiplex imaging, and digital technologies have further deciphered the diversity of B cells and the morphological structures in which they appear in the tumour and LNs. Thus, in this review, we comprehensively summarise the current knowledge of B cells in breast cancer. In addition, we provide a user-friendly single-cell RNA-sequencing platform, called "B singLe cEll rna-Seq browSer" (BLESS) platform, with a focus on the B cells in breast cancer patients to interrogate the latest publicly available single-cell RNA-sequencing data collected from diverse breast cancer studies. Finally, we explore their clinical relevance as biomarkers or molecular targets for future interventions.

Original language	English
Article number	1517
Journal	Cancers
Volume	15
Issue number	5
DOIs	https://doi.org/10.3390/cancers15051517
Publication status	Published - 28 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers15051517

Cite this

@article{f85095c3c1004db1a0e939b2fd9f52c1,

title = "B Cells in Breast Cancer Pathology",

abstract = "B cells have recently become a focus in breast cancer pathology due to their influence on tumour regression, prognosis, and response to treatment, besides their contribution to antigen presentation, immunoglobulin production, and regulation of adaptive responses. As our understanding of diverse B cell subsets in eliciting both pro- and anti-inflammatory responses in breast cancer patients increases, it has become pertinent to address the molecular and clinical relevance of these immune cell populations within the tumour microenvironment (TME). At the primary tumour site, B cells are either found spatially dispersed or aggregated in so-called tertiary lymphoid structures (TLS). In axillary lymph nodes (LNs), B cell populations, amongst a plethora of activities, undergo germinal centre reactions to ensure humoral immunity. With the recent approval for the addition of immunotherapeutic drugs as a treatment option in the early and metastatic settings for triple-negative breast cancer (TNBC) patients, B cell populations or TLS may resemble valuable biomarkers for immunotherapy responses in certain breast cancer subgroups. New technologies such as spatially defined sequencing techniques, multiplex imaging, and digital technologies have further deciphered the diversity of B cells and the morphological structures in which they appear in the tumour and LNs. Thus, in this review, we comprehensively summarise the current knowledge of B cells in breast cancer. In addition, we provide a user-friendly single-cell RNA-sequencing platform, called {"}B singLe cEll rna-Seq browSer{"} (BLESS) platform, with a focus on the B cells in breast cancer patients to interrogate the latest publicly available single-cell RNA-sequencing data collected from diverse breast cancer studies. Finally, we explore their clinical relevance as biomarkers or molecular targets for future interventions.",

author = "Mengyuan Li and Angela Quintana and Elena Alberts and Hung, {Miu Shing} and Victoire Boulat and Ripoll, {Merc{\`e} Mart{\'i}} and Anita Grigoriadis",

note = "Funding Information: The authors acknowledge support by Breast Cancer Now (KCL-BCN-Q3), the Medical Research Council [MR/X012476/1]; Mengyuan Li was awarded funds by the China Scholarship Council [202008440233]; Elena Alberts was funded by the UK Medical Research Council Doctoral Training Programme; Victoire Boulat was awarded funds by Cancer Research UK (RE18831). Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = feb,

day = "28",

doi = "10.3390/cancers15051517",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - B Cells in Breast Cancer Pathology

AU - Li, Mengyuan

AU - Quintana, Angela

AU - Alberts, Elena

AU - Hung, Miu Shing

AU - Boulat, Victoire

AU - Ripoll, Mercè Martí

AU - Grigoriadis, Anita

N1 - Funding Information: The authors acknowledge support by Breast Cancer Now (KCL-BCN-Q3), the Medical Research Council [MR/X012476/1]; Mengyuan Li was awarded funds by the China Scholarship Council [202008440233]; Elena Alberts was funded by the UK Medical Research Council Doctoral Training Programme; Victoire Boulat was awarded funds by Cancer Research UK (RE18831). Publisher Copyright: © 2023 by the authors.

PY - 2023/2/28

Y1 - 2023/2/28

N2 - B cells have recently become a focus in breast cancer pathology due to their influence on tumour regression, prognosis, and response to treatment, besides their contribution to antigen presentation, immunoglobulin production, and regulation of adaptive responses. As our understanding of diverse B cell subsets in eliciting both pro- and anti-inflammatory responses in breast cancer patients increases, it has become pertinent to address the molecular and clinical relevance of these immune cell populations within the tumour microenvironment (TME). At the primary tumour site, B cells are either found spatially dispersed or aggregated in so-called tertiary lymphoid structures (TLS). In axillary lymph nodes (LNs), B cell populations, amongst a plethora of activities, undergo germinal centre reactions to ensure humoral immunity. With the recent approval for the addition of immunotherapeutic drugs as a treatment option in the early and metastatic settings for triple-negative breast cancer (TNBC) patients, B cell populations or TLS may resemble valuable biomarkers for immunotherapy responses in certain breast cancer subgroups. New technologies such as spatially defined sequencing techniques, multiplex imaging, and digital technologies have further deciphered the diversity of B cells and the morphological structures in which they appear in the tumour and LNs. Thus, in this review, we comprehensively summarise the current knowledge of B cells in breast cancer. In addition, we provide a user-friendly single-cell RNA-sequencing platform, called "B singLe cEll rna-Seq browSer" (BLESS) platform, with a focus on the B cells in breast cancer patients to interrogate the latest publicly available single-cell RNA-sequencing data collected from diverse breast cancer studies. Finally, we explore their clinical relevance as biomarkers or molecular targets for future interventions.

AB - B cells have recently become a focus in breast cancer pathology due to their influence on tumour regression, prognosis, and response to treatment, besides their contribution to antigen presentation, immunoglobulin production, and regulation of adaptive responses. As our understanding of diverse B cell subsets in eliciting both pro- and anti-inflammatory responses in breast cancer patients increases, it has become pertinent to address the molecular and clinical relevance of these immune cell populations within the tumour microenvironment (TME). At the primary tumour site, B cells are either found spatially dispersed or aggregated in so-called tertiary lymphoid structures (TLS). In axillary lymph nodes (LNs), B cell populations, amongst a plethora of activities, undergo germinal centre reactions to ensure humoral immunity. With the recent approval for the addition of immunotherapeutic drugs as a treatment option in the early and metastatic settings for triple-negative breast cancer (TNBC) patients, B cell populations or TLS may resemble valuable biomarkers for immunotherapy responses in certain breast cancer subgroups. New technologies such as spatially defined sequencing techniques, multiplex imaging, and digital technologies have further deciphered the diversity of B cells and the morphological structures in which they appear in the tumour and LNs. Thus, in this review, we comprehensively summarise the current knowledge of B cells in breast cancer. In addition, we provide a user-friendly single-cell RNA-sequencing platform, called "B singLe cEll rna-Seq browSer" (BLESS) platform, with a focus on the B cells in breast cancer patients to interrogate the latest publicly available single-cell RNA-sequencing data collected from diverse breast cancer studies. Finally, we explore their clinical relevance as biomarkers or molecular targets for future interventions.

UR - http://www.scopus.com/inward/record.url?scp=85149867325&partnerID=8YFLogxK

U2 - 10.3390/cancers15051517

DO - 10.3390/cancers15051517

M3 - Review article

C2 - 36900307

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 5

M1 - 1517

ER -

B Cells in Breast Cancer Pathology

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this